News Image

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Provided By GlobeNewswire

Last update: Jun 17, 2025

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), for current good manufacturing practice (cGMP) manufacturing of MT-601, Marker’s lead Multi-Antigen Recognizing (MAR)-T cell therapy.

Read more at globenewswire.com

MARKER THERAPEUTICS INC

NASDAQ:MRKR (6/30/2025, 8:00:01 PM)

After market: 1.53 0 (0%)

1.53

+0.07 (+4.79%)



Find more stocks in the Stock Screener

Follow ChartMill for more